The neutralizing antibody HGF or IL-6 has been used to successfully reverse the stem cell viability of CD24+ HCC cells in vitro and in vivo through the HGF/C-MET/STAT3 or IL6/IL6R/STAT3 signaling pathways (138). The gene discussed is STAT3; the disease is hepatocellular carcinoma.